Literature DB >> 20359627

The genetic basis of myelodysplastic syndromes.

Rafael Bejar1, Benjamin L Ebert.   

Abstract

Myelodysplastic syndrome (MDS) disorders are clonal diseases that often carry stereotypic chromosomal abnormalities. A smaller proportion of cases harbor point mutations that activate oncogenes or inactivate tumor suppressor genes. New technologies have accelerated the pace of discovery and are responsible for the identification of novel genetic mutations associated with MDS and other myeloid neoplasms. These discoveries have identified novel mechanisms in the pathogenesis of MDS. This article touches on the better known genetic abnormalities in MDS and explains in greater detail those that have been discovered more recently. Understanding how mutations lead to MDS and how they might cooperate with each other has become more complicated as the number of MDS-associated genetic abnormalities has grown. In some cases, these mutations have prognostic significance that could improve upon the various prognostic scoring systems in common clinical use. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20359627     DOI: 10.1016/j.hoc.2010.02.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  8 in total

Review 1.  Epigenetics in myelodysplastic syndromes.

Authors:  Michael Heuser; Haiyang Yun; Felicitas Thol
Journal:  Semin Cancer Biol       Date:  2017-08-02       Impact factor: 15.707

Review 2.  Myelodysplastic Syndromes: Updates and Nuances.

Authors:  Kim-Hien T Dao
Journal:  Med Clin North Am       Date:  2017-03       Impact factor: 5.456

Review 3.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

Review 4.  Genetic deletions in AML and MDS.

Authors:  Benjamin L Ebert
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-04       Impact factor: 3.020

5.  NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.

Authors:  D M Murphy; R Bejar; K Stevenson; D Neuberg; Y Shi; C Cubrich; K Richardson; P Eastlake; G Garcia-Manero; H Kantarjian; B L Ebert; G Mike Makrigiorgos
Journal:  Leukemia       Date:  2013-05-27       Impact factor: 11.528

Review 6.  Implication of microRNAs in the pathogenesis of MDS.

Authors:  Jing Fang; Melinda Varney; Daniel T Starczynowski
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.

Authors:  Hyun Ae Jung; Chi Hoon Maeng; Moonjin Kim; Sungmin Kim; Chul Won Jung; Jun Ho Jang
Journal:  Oncotarget       Date:  2015-06-30

8.  Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.

Authors:  Hyun Ae Jung; Chul Won Jung; Jun Ho Jang
Journal:  Korean J Intern Med       Date:  2020-10-23       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.